Clara Crescioli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Clara Crescioli has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Lenzi
Department of Experimental Medicine, Sapienza University of Rome, V.le Regina Elena 324, 00161 Rome, Italy
11 shared publications Luigi Di Luigi
Università degli Studi di Roma “Foro Italico
6 shared publicationsA. Lenzi
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
5 shared publicationsCristina Antinozzi
Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy
5 shared publicationsL. Di Luigi
Unit of Endocrinology, Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", 00135, Rome, Italy
5 shared publications- Susanna Morano
Department of Experimental Medicine, “Sapienza” University, Viale Regina Elena 324, 00161 Rome, Italy
5 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1325
CXCL10 Is Inhibited by PPARβ/δ-Selective Activation in Human Monocyte-Derived Dendritic Cells, T Lymphocytes and Monocytes In Vitro: Insights into Autoimmune Rheumatic Diseases
The chemokine CXCL10 contributes to early autoimmune rheumatic disease (ARD) development. Preclinical ARD stages exhibit dendritic cells (DCs), CD4+ T cells, and monocytes (CD14+ cells) dysregulation and an overreactive immunoprofile. The peroxisome proliferator-activated receptor (PPAR)β/δ acts as a “molecular brake”, limiting autoimmune overresponse. This study aims to investigate CXCL10 in human monocyte-derived mDCs, CD4+ T cells, and monocytes exposed to PPARβ/δ agonist carbaprostacylin (cPGI2) or PPARγ agonist rosiglitazone (RGZ), to verify drug-class-related effects. Tumor necrosis factor (TNF)α, interferon (IFN)γ, synergistic inducers of CXCL10, and interleukin (IL)-10 were investigated. mDCs, CD4+ T cells, and CD14+ monocytes isolated from healthy donors’ blood were cultured, specifically activated to mimic an overreactive phenotype, and treated for 24–48 h with/without [10 μM] cPGI2 or [5 μM] RGZ (near therapy doses, respectively). Luminex assays quantified cell supernatant analytes; Real-time q-PCR measured cytokine and PPARβ/δ mRNA expression. cPGI2, not RGZ, significantly decreased CXCL10 in mDCs and CD4+ T cells, reduced TNFα in mDCs, CD4+ T and monocytes, and diminished IFNγ in mDCs. IL-10 did not change. cPGI2-induced CXCL10 downregulation, with TNFα and IFNγ decrease, might be relevant, given its early activity in ARD development. Scenarios on PPARβ/δ agonist re-positioning aimed at modulating CXCL10 might open opportunities to support ARD management and targeted therapy development.
- 11 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1325
Open AccessCXCL10 Is Inhibited by PPARβ/δ-Selective Activation in Human Monocyte-Derived Dendritic Cells, T Lymphocytes and Monocytes In Vitro: Insights into Autoimmune Rheumatic Diseases
The chemokine CXCL10 contributes to early autoimmune rheumatic disease (ARD) development. Preclinical ARD stages exhibit dendritic cells (DCs), CD4+ T cells, and monocytes (CD14+ cells) dysregulation and an overreactive immunoprofile. The peroxisome proliferator-activated receptor (PPAR)β/δ acts as a “molecular brake”, limiting autoimmune overresponse. This study aims to investigate CXCL10 in human monocyte-derived mDCs, CD4+ T cells, and monocytes exposed to PPARβ/δ agonist carbaprostacylin (cPGI2) or PPARγ agonist rosiglitazone (RGZ), to verify drug-class-related effects. Tumor necrosis factor (TNF)α, interferon (IFN)γ, synergistic inducers of CXCL10, and interleukin (IL)-10 were investigated. mDCs, CD4+ T cells, and CD14+ monocytes isolated from healthy donors’ blood were cultured, specifically activated to mimic an overreactive phenotype, and treated for 24–48 h with/without [10 μM] cPGI2 or [5 μM] RGZ (near therapy doses, respectively). Luminex assays quantified cell supernatant analytes; Real-time q-PCR measured cytokine and PPARβ/δ mRNA expression. cPGI2, not RGZ, significantly decreased CXCL10 in mDCs and CD4+ T cells, reduced TNFα in mDCs, CD4+ T and monocytes, and diminished IFNγ in mDCs. IL-10 did not change. cPGI2-induced CXCL10 downregulation, with TNFα and IFNγ decrease, might be relevant, given its early activity in ARD development. Scenarios on PPARβ/δ agonist re-positioning aimed at modulating CXCL10 might open opportunities to support ARD management and targeted therapy development.
- Open Access
Synaptic Plasticity in Neurodegenerative Diseases: Impact of Exercise as Promising Therapeutic Tool
Neurodegenerative diseases are distinguished by synaptic dysfunction and chronic neuroinflammation, which accelerate neuronal loss and impair network resilience. Synaptic plasticity, that is, the ability to adapt to changes, is progressively lost. This ability is part of hormesis, an adaptive biphasic response, nowadays acknowledged as a promising tool in chronic degenerative diseases, since it offers a framework for personalized interventions. Growing evidence supports exercise as a powerful approach for managing neurodegenerative disorders, due to its capacity to enhance neuroplasticity through the direct targeting of the biomolecular processes involved. Indeed, regular exercise can drive many molecular mediators and signals toward neuroplasticity improvement, potentially slowing neurodegeneration. This narrative review focuses on exercise as a promising therapeutic approach in neurodegenerative diseases, based on its ability to shape synaptic plasticity at the molecular level. Some biomediators involved in synaptic plasticity function/dysfunction and neuroinflammation/neurodegeneration are addressed as therapeutic targets of exercise, and different exercise regimens are discussed as specific therapeutic interventions to contain the burden of some neurodegenerative conditions. Some clinical trials including exercise in the treatment of neurodegenerative diseases are summarized. Since no definitive disease-modifying cure exists for these illnesses, exercise’s ability to shape synaptic plasticity emerges as a highly attractive therapeutic approach.
Open AccessSynaptic Plasticity in Neurodegenerative Diseases: Impact of Exercise as Promising Therapeutic Tool
Neurodegenerative diseases are distinguished by synaptic dysfunction and chronic neuroinflammation, which accelerate neuronal loss and impair network resilience. Synaptic plasticity, that is, the ability to adapt to changes, is progressively lost. This ability is part of hormesis, an adaptive biphasic response, nowadays acknowledged as a promising tool in chronic degenerative diseases, since it offers a framework for personalized interventions. Growing evidence supports exercise as a powerful approach for managing neurodegenerative disorders, due to its capacity to enhance neuroplasticity through the direct targeting of the biomolecular processes involved. Indeed, regular exercise can drive many molecular mediators and signals toward neuroplasticity improvement, potentially slowing neurodegeneration. This narrative review focuses on exercise as a promising therapeutic approach in neurodegenerative diseases, based on its ability to shape synaptic plasticity at the molecular level. Some biomediators involved in synaptic plasticity function/dysfunction and neuroinflammation/neurodegeneration are addressed as therapeutic targets of exercise, and different exercise regimens are discussed as specific therapeutic interventions to contain the burden of some neurodegenerative conditions. Some clinical trials including exercise in the treatment of neurodegenerative diseases are summarized. Since no definitive disease-modifying cure exists for these illnesses, exercise’s ability to shape synaptic plasticity emerges as a highly attractive therapeutic approach.
- Open Access
Vitamin D Associated with Exercise Can Be Used as a Promising Tool in Neurodegenerative Disease Protection
Neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and Huntington’s disease, represent unmet medical and social needs. Still, no definitive cure exists for these illnesses, hence a therapeutic approach with molecules able to prevent/downtone/modify the disease seems highly attractive. Remarkably, a higher risk of neurodegenerative disease is associated with low vitamin D levels. Vitamin D is a multifaceted molecule able to target critical neuroinflammatory processes underlying neurodegeneration, acting through genomic or rapid signaling. This narrative review aims to focus on vitamin D’s potential to be an optimal neuroprotective molecule, based on its ability to target and counteract aberrant biomolecular processes involved in neuroinflammation/neurodegeneration. Noticeably, exercise can potentiate vitamin D’s protective effect through some anti-inflammatory actions exerted on shared biomolecular targets. Thus, although vitamin D is not strictly a drug, it could be potentially allocated within the therapeutic approach to neurodegenerative diseases in combination with adapted exercise, best as an early intervention. Topics on the complexity concerning the doses for supplementation and data discrepancy from trials are addressed. The urgent demand is to test and clarify vitamin D efficacy and safety, combined or not with exercise, in clinical settings.
Open AccessVitamin D Associated with Exercise Can Be Used as a Promising Tool in Neurodegenerative Disease Protection
Neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and Huntington’s disease, represent unmet medical and social needs. Still, no definitive cure exists for these illnesses, hence a therapeutic approach with molecules able to prevent/downtone/modify the disease seems highly attractive. Remarkably, a higher risk of neurodegenerative disease is associated with low vitamin D levels. Vitamin D is a multifaceted molecule able to target critical neuroinflammatory processes underlying neurodegeneration, acting through genomic or rapid signaling. This narrative review aims to focus on vitamin D’s potential to be an optimal neuroprotective molecule, based on its ability to target and counteract aberrant biomolecular processes involved in neuroinflammation/neurodegeneration. Noticeably, exercise can potentiate vitamin D’s protective effect through some anti-inflammatory actions exerted on shared biomolecular targets. Thus, although vitamin D is not strictly a drug, it could be potentially allocated within the therapeutic approach to neurodegenerative diseases in combination with adapted exercise, best as an early intervention. Topics on the complexity concerning the doses for supplementation and data discrepancy from trials are addressed. The urgent demand is to test and clarify vitamin D efficacy and safety, combined or not with exercise, in clinical settings.
- Open Access
- 15 May 2025
- Published by Elsevier in Trends in Cancer
Repurposing glucose-lowering drugs for cancer therapy
- 15 May 2025
- Published by Elsevier in Trends in Cancer
Open AccessRepurposing glucose-lowering drugs for cancer therapy
- Top Cited PapersOpen Access
- 7 November 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (11) , 1418
How Does Physical Activity Modulate Hormone Responses?
Physical activity highly impacts the neuroendocrine system and hormonal secretion. Numerous variables, both those related to the individual, including genetics, age, sex, biological rhythms, nutritional status, level of training, intake of drugs or supplements, and previous or current pathologies, and those related to the physical activity in terms of type, intensity, and duration of exercise, or environmental conditions can shape the hormonal response to physical exercise. The aim of this review is to provide an overview of the effects of physical exercise on hormonal levels in the human body, focusing on changes in concentrations of hormones such as cortisol, testosterone, and insulin in response to different types and intensities of physical activity. Regular monitoring of hormonal responses in athletes could be a potential tool to design individual training programs and prevent overtraining syndrome.
- 7 November 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (11) , 1418
Top Cited PapersOpen AccessHow Does Physical Activity Modulate Hormone Responses?
Physical activity highly impacts the neuroendocrine system and hormonal secretion. Numerous variables, both those related to the individual, including genetics, age, sex, biological rhythms, nutritional status, level of training, intake of drugs or supplements, and previous or current pathologies, and those related to the physical activity in terms of type, intensity, and duration of exercise, or environmental conditions can shape the hormonal response to physical exercise. The aim of this review is to provide an overview of the effects of physical exercise on hormonal levels in the human body, focusing on changes in concentrations of hormones such as cortisol, testosterone, and insulin in response to different types and intensities of physical activity. Regular monitoring of hormonal responses in athletes could be a potential tool to design individual training programs and prevent overtraining syndrome.
- Open Access
The Emerging Role of Phosphodiesterase 5 Inhibition in Neurological Disorders: The State of the Art
Growing evidence suggests that neuroinflammation is not just a consequence of neurodegeneration in pathologies such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease or Amyotrophic lateral sclerosis, but it is rather a determinant factor, which plays a pivotal role in the onset and progression of these disorders. Neuroinflammation can affect cells and processes in the central nervous system (CNS) as well as immune cells, and might precede protein aggregation, which is a hallmark of the neurodegenerative process. Standard treatment methods are far from being able to counteract inflammation and delay neurodegeneration. Remarkably, phosphodiesterase 5 inhibitors (PDE5is), which represent potent vasoactive drugs used as a first-line treatment for erectile dysfunction (ED), display important anti-inflammatory effects through cyclic guanosine monophosphate (cGMP) level stabilization. Since PDE5 hydrolyzes cGMP, several studies positioned PDE5 as a therapeutic target, and more specifically, PDE5is as potential alternative strategies for the treatment of a variety of neurological disorders. Indeed, PDE5is can limit neuroinflammation and enhance synaptic plasticity, with beneficial effects on cognitive function and memory. The aim of this review is to provide an overview of some of the main processes underlying neuroinflammation and neurodegeneration which may be potential targets for PDE5is, focusing on sildenafil, the most extensively studied. Current strategies using PDEis for the treatment of neurodegenerative diseases will be summarized.
Open AccessThe Emerging Role of Phosphodiesterase 5 Inhibition in Neurological Disorders: The State of the Art
Growing evidence suggests that neuroinflammation is not just a consequence of neurodegeneration in pathologies such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease or Amyotrophic lateral sclerosis, but it is rather a determinant factor, which plays a pivotal role in the onset and progression of these disorders. Neuroinflammation can affect cells and processes in the central nervous system (CNS) as well as immune cells, and might precede protein aggregation, which is a hallmark of the neurodegenerative process. Standard treatment methods are far from being able to counteract inflammation and delay neurodegeneration. Remarkably, phosphodiesterase 5 inhibitors (PDE5is), which represent potent vasoactive drugs used as a first-line treatment for erectile dysfunction (ED), display important anti-inflammatory effects through cyclic guanosine monophosphate (cGMP) level stabilization. Since PDE5 hydrolyzes cGMP, several studies positioned PDE5 as a therapeutic target, and more specifically, PDE5is as potential alternative strategies for the treatment of a variety of neurological disorders. Indeed, PDE5is can limit neuroinflammation and enhance synaptic plasticity, with beneficial effects on cognitive function and memory. The aim of this review is to provide an overview of some of the main processes underlying neuroinflammation and neurodegeneration which may be potential targets for PDE5is, focusing on sildenafil, the most extensively studied. Current strategies using PDEis for the treatment of neurodegenerative diseases will be summarized.
- Open Access
- 17 September 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1461642
Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
The phosphodiesterases type 5 (PDE5) are catalytic enzymes converting the second messenger cyclic guanosine monophosphate (cGMP) to 5’ GMP. While intracellular cGMP reduction is associated with several detrimental effects, cGMP stabilization associates with numerous benefits. The PDE5 specific inhibitors, PDE5i, found their explosive fortune as first-line treatment for erectile dysfunction (ED), due to their powerful vasoactive properties. The favorable effect for ED emerged as side-effect when PDE5i were originally proposed for coronary artery disease (CAD). From that point on, the use of PDE5i captured the attention of researchers, clinicians, and companies. Indeed, PDE5-induced intracellular cGMP stabilization offers a range of therapeutic opportunities associated not only with vasoactive effects, but also with immune regulatory/anti-inflammatory actions. Chronic inflammation is acknowledged as the common link underlying most non-communicable diseases, including metabolic and cardiac diseases, autoimmune and neurodegenerative disorders, cancer. In this scenario, the clinical exploitation of PDE5i is undeniably beyond ED, representing a potential therapeutic tool in several human diseases. This review aims to overview the biological actions exerted by PDE5i, focusing on their ability as modulators of inflammation-related human diseases, with particular attention to inflammatory-related disorders, like cardiac diseases and cancer.
- 17 September 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1461642
Open AccessRethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
The phosphodiesterases type 5 (PDE5) are catalytic enzymes converting the second messenger cyclic guanosine monophosphate (cGMP) to 5’ GMP. While intracellular cGMP reduction is associated with several detrimental effects, cGMP stabilization associates with numerous benefits. The PDE5 specific inhibitors, PDE5i, found their explosive fortune as first-line treatment for erectile dysfunction (ED), due to their powerful vasoactive properties. The favorable effect for ED emerged as side-effect when PDE5i were originally proposed for coronary artery disease (CAD). From that point on, the use of PDE5i captured the attention of researchers, clinicians, and companies. Indeed, PDE5-induced intracellular cGMP stabilization offers a range of therapeutic opportunities associated not only with vasoactive effects, but also with immune regulatory/anti-inflammatory actions. Chronic inflammation is acknowledged as the common link underlying most non-communicable diseases, including metabolic and cardiac diseases, autoimmune and neurodegenerative disorders, cancer. In this scenario, the clinical exploitation of PDE5i is undeniably beyond ED, representing a potential therapeutic tool in several human diseases. This review aims to overview the biological actions exerted by PDE5i, focusing on their ability as modulators of inflammation-related human diseases, with particular attention to inflammatory-related disorders, like cardiac diseases and cancer.
- Open Access
- 18 August 2023
- Published by Elsevier in Autoimmunity Reviews
- Vol. 22 (10) , 103412
Exercise-induced modulation of Interferon-signature: a therapeutic route toward management of Systemic Lupus Erythematosus
- 18 August 2023
- Published by Elsevier in Autoimmunity Reviews
- Vol. 22 (10) , 103412
Open AccessExercise-induced modulation of Interferon-signature: a therapeutic route toward management of Systemic Lupus Erythematosus
- Top Cited PapersOpen Access
- 25 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (5) , 4546
Vitamin D as a Shield against Aging
Aging can be seen as a physiological progression of biomolecular damage and the accumulation of defective cellular components, which trigger and amplify the process, toward whole-body function weakening. Senescence initiates at the cellular level and consists in an inability to maintain homeostasis, characterized by the overexpression/aberrant expression of inflammatory/immune/stress responses. Aging is associated with significant modifications in immune system cells, toward a decline in immunosurveillance, which, in turn, leads to chronic elevation of inflammation/oxidative stress, increasing the risk of (co)morbidities. Albeit aging is a natural and unavoidable process, it can be regulated by some factors, like lifestyle and diet. Nutrition, indeed, tackles the mechanisms underlying molecular/cellular aging. Many micronutrients, i.e., vitamins and elements, can impact cell function. This review focuses on the role exerted by vitamin D in geroprotection, based on its ability to shape cellular/intracellular processes and drive the immune response toward immune protection against infections and age-related diseases. To this aim, the main biomolecular paths underlying immunosenescence and inflammaging are identified as biotargets of vitamin D. Topics such as heart and skeletal muscle cell function/dysfunction, depending on vitamin D status, are addressed, with comments on hypovitaminosis D correction by food and supplementation. Albeit research has progressed, still limitations exist in translating knowledge into clinical practice, making it necessary to focus attention on the role of vitamin D in aging, especially considering the growing number of older individuals.
- 25 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (5) , 4546
Top Cited PapersOpen AccessVitamin D as a Shield against Aging
Aging can be seen as a physiological progression of biomolecular damage and the accumulation of defective cellular components, which trigger and amplify the process, toward whole-body function weakening. Senescence initiates at the cellular level and consists in an inability to maintain homeostasis, characterized by the overexpression/aberrant expression of inflammatory/immune/stress responses. Aging is associated with significant modifications in immune system cells, toward a decline in immunosurveillance, which, in turn, leads to chronic elevation of inflammation/oxidative stress, increasing the risk of (co)morbidities. Albeit aging is a natural and unavoidable process, it can be regulated by some factors, like lifestyle and diet. Nutrition, indeed, tackles the mechanisms underlying molecular/cellular aging. Many micronutrients, i.e., vitamins and elements, can impact cell function. This review focuses on the role exerted by vitamin D in geroprotection, based on its ability to shape cellular/intracellular processes and drive the immune response toward immune protection against infections and age-related diseases. To this aim, the main biomolecular paths underlying immunosenescence and inflammaging are identified as biotargets of vitamin D. Topics such as heart and skeletal muscle cell function/dysfunction, depending on vitamin D status, are addressed, with comments on hypovitaminosis D correction by food and supplementation. Albeit research has progressed, still limitations exist in translating knowledge into clinical practice, making it necessary to focus attention on the role of vitamin D in aging, especially considering the growing number of older individuals.
- Open Access
- 1 January 2023
- Published by Polaris in International Journal of Veterinary Research and Allied Science
- Vol. 3 (2) , 14-19
Modulation of Hormonal Homeostasis and Blood Biochemical Markers by Non-Hormonal Drugs
The physiological processes within an organism, along with external influences, inevitably change the composition of the blood to varying extents. Accurate biochemical and hematological analysis of blood parameters is very important for proper diagnosis and the selection of therapeutic interventions. When administering various drugs, especially proteinmineral complexes and essential micro-and macroelements, it is necessary to understand their overall effect on the body. This study examines the effects of a non-hormonal complex aimed at regulating hormonal balance, using sheep as a model. Over 50 days, animals in the experimental group received a daily dose of 5 ml of an iodine-amylodextrin preparation, along with injections of 1.5 ml of E-selenium and 0.5 ml of a tissue-based preparation mixed with 1 milliliter of a 0.5% solution of novocaine. After the study, protein metabolism and the dynamics of carbohydrate-lipid metabolism were analyzed. The findings indicate that the nonhormonal agents administered do not harm the body and instead contribute to a more efficient recovery process.
- 1 January 2023
- Published by Polaris in International Journal of Veterinary Research and Allied Science
- Vol. 3 (2) , 14-19
Open AccessModulation of Hormonal Homeostasis and Blood Biochemical Markers by Non-Hormonal Drugs
The physiological processes within an organism, along with external influences, inevitably change the composition of the blood to varying extents. Accurate biochemical and hematological analysis of blood parameters is very important for proper diagnosis and the selection of therapeutic interventions. When administering various drugs, especially proteinmineral complexes and essential micro-and macroelements, it is necessary to understand their overall effect on the body. This study examines the effects of a non-hormonal complex aimed at regulating hormonal balance, using sheep as a model. Over 50 days, animals in the experimental group received a daily dose of 5 ml of an iodine-amylodextrin preparation, along with injections of 1.5 ml of E-selenium and 0.5 ml of a tissue-based preparation mixed with 1 milliliter of a 0.5% solution of novocaine. After the study, protein metabolism and the dynamics of carbohydrate-lipid metabolism were analyzed. The findings indicate that the nonhormonal agents administered do not harm the body and instead contribute to a more efficient recovery process.